Quinoline derivatives' biological interest for anti-malarial and anti-cancer activities: an overview.
| Title: | Quinoline derivatives' biological interest for anti-malarial and anti-cancer activities: an overview. |
|---|---|
| Authors: | Chavan ND; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology Vellore 632016 India chavannagesh605@gmail.com vvijayakumar@vit.ac.in kvpsvijayakumar@gmail.com.; Sarveswari S; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology Vellore 632016 India chavannagesh605@gmail.com vvijayakumar@vit.ac.in kvpsvijayakumar@gmail.com.; Vijayakumar V; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology Vellore 632016 India chavannagesh605@gmail.com vvijayakumar@vit.ac.in kvpsvijayakumar@gmail.com. |
| Source: | RSC advances [RSC Adv] 2025 Aug 27; Vol. 15 (37), pp. 30576-30604. Date of Electronic Publication: 2025 Aug 27 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101581657 Publication Model: eCollection Cited Medium: Internet ISSN: 2046-2069 (Electronic) Linking ISSN: 20462069 NLM ISO Abbreviation: RSC Adv Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Cambridge [England] : Royal Society of Chemistry, [2011]- |
| Abstract: | Quinoline is a heterocyclic compound that plays a fundamental role in the study of chemical compounds, highlighting its importance in drug development. Its basic framework is crucial for synthesizing new pharmaceutical substances and facilitating the development of innovative drugs with significant therapeutic potential. A thorough examination of quinoline and its various derivatives, which exhibit a wide range of biological activities, greatly contributes to groundbreaking drug discoveries that can transform the medical industry. This review presents a carefully curated collection of references related to quinoline, covering a unique range of quinoline-based medications currently available on the market, including antimalarial and anticancer drugs. It provides a comprehensive overview of the therapeutic potential of these compounds. Furthermore, the review aims to clarify and explain the complex biological properties of quinoline derivatives, particularly their antimalarial and anticancer activities. This insight will enhance our understanding of the therapeutic potential and efficacy of these compounds in combating malaria and cancer, diseases that affect millions of people worldwide.; (This journal is © The Royal Society of Chemistry.) |
| Competing Interests: | The authors report has no conflict of interest. |
| References: | J Med Chem. 2007 Feb 22;50(4):889-96. (PMID: 17266295); Pharmacol Ther. 1998 Jul;79(1):55-87. (PMID: 9719345); J Med Chem. 2013 Feb 28;56(4):1431-42. (PMID: 23360309); ACS Omega. 2021 May 11;6(20):12984-12994. (PMID: 34056449); Adv Exp Med Biol. 2020;1282:37-69. (PMID: 31515709); Eur J Med Chem. 2017 Oct 20;139:22-47. (PMID: 28800458); J Med Chem. 2010 Sep 9;53(17):6477-89. (PMID: 20684562); J Med Chem. 2009 Apr 9;52(7):1828-44. (PMID: 19284751); ChemMedChem. 2020 Apr 3;15(7):600-609. (PMID: 32068948); J Med Chem. 2011 Dec 22;54(24):8321-7. (PMID: 22111907); RSC Adv. 2020 Aug 21;10(52):31139-31155. (PMID: 35520674); Bioorg Med Chem. 2014 May 1;22(9):2629-42. (PMID: 24721829); Molecules. 2024 Aug 26;29(17):. (PMID: 39274892); Expert Opin Ther Pat. 2016 Oct;26(10):1201-21. (PMID: 27458877); Arch Pharm (Weinheim). 2021 Mar;354(3):e2000232. (PMID: 33210348); J Med Chem. 2020 Oct 22;63(20):11756-11785. (PMID: 32959656); ACS Med Chem Lett. 2019 Mar 13;10(5):714-719. (PMID: 31097988); Bioorg Chem. 2021 Jan;106:104511. (PMID: 33272707); Appl Biochem Biotechnol. 2015 Jan;175(1):43-64. (PMID: 25238919); Eur J Med Chem. 2021 Apr 5;215:113261. (PMID: 33631697); Int J Mol Sci. 2023 Apr 09;24(8):. (PMID: 37108135); Chemistry. 2021 Mar 1;27(13):4230-4248. (PMID: 33137212); Eur J Med Chem. 2012 Aug;54:239-47. (PMID: 22652224); Bioorg Chem. 2018 Dec;81:184-190. (PMID: 30138906); Chem Rev. 2009 Jul;109(7):2894-902. (PMID: 19476377); Arch Pharm (Weinheim). 2021 Sep;354(9):e2100094. (PMID: 34050547); Bioorg Chem. 2017 Dec;75:368-392. (PMID: 29096097); Bioorg Med Chem. 2009 Jan 1;17(1):203-21. (PMID: 19058973); J Med Chem. 2010 Apr 22;53(8):3214-26. (PMID: 20329733); Eur J Med Chem. 2020 Dec 15;208:112756. (PMID: 32942186); Bioorg Chem. 2020 May;98:103711. (PMID: 32179282); Int J Parasitol. 1997 Feb;27(2):231-40. (PMID: 9088993); Eur J Med Chem. 2021 Mar 15;214:113249. (PMID: 33561608); Bioorg Chem. 2025 Apr;157:108247. (PMID: 39983403); Bioorg Chem. 2021 Jul;112:104949. (PMID: 34023640); Bioorg Med Chem Lett. 2007 Oct 15;17(20):5683-5. (PMID: 17768052); Bioorg Med Chem. 2024 Apr 1;103:117681. (PMID: 38492541); Bioorg Med Chem Lett. 2019 Apr 1;29(7):917-922. (PMID: 30738663); ACS Med Chem Lett. 2018 Oct 19;9(12):1205-1210. (PMID: 30613327); ACS Med Chem Lett. 2018 Feb 23;9(3):283-288. (PMID: 29541375); Curr Med Chem. 2013;20(35):4386-410. (PMID: 23862618); Bioorg Med Chem Lett. 2015 Jun 1;25(11):2308-13. (PMID: 25920564); J Med Chem. 2013 Aug 8;56(15):6200-15. (PMID: 23837878); RSC Adv. 2025 Jan 21;15(3):1941-1956. (PMID: 39839233); Bioorg Chem. 2024 Oct;151:107674. (PMID: 39059071); J Med Chem. 2016 Nov 10;59(21):9672-9685. (PMID: 27631715); Saudi Pharm J. 2013 Jan;21(1):1-12. (PMID: 23960814); Bioorg Chem. 2022 Feb;119:105469. (PMID: 34915285); Mycobiology. 2024 Dec 3;52(6):335-387. (PMID: 39845176); Heliyon. 2024 Feb 29;10(5):e26735. (PMID: 38468950); J Med Chem. 2011 Jan 13;54(1):131-42. (PMID: 21141892); Bioorg Med Chem. 2020 Jun 1;28(11):115511. (PMID: 32336669); Pharmaceuticals (Basel). 2023 Sep 26;16(10):. (PMID: 37895829); Sci Rep. 2025 Mar 31;15(1):10972. (PMID: 40164813); Eur J Med Chem. 2015 Jun 5;97:871-910. (PMID: 25073919); ACS Med Chem Lett. 2021 Apr 27;12(5):822-826. (PMID: 34055232); J Med Chem. 2019 Apr 11;62(7):3428-3446. (PMID: 30897325); Int J Cancer. 2012 Apr 1;130(7):1660-70. (PMID: 21544805); Eur J Med Chem. 2023 Nov 15;260:115772. (PMID: 37659195); J Med Chem. 2016 Nov 10;59(21):9668-9671. (PMID: 27775354); Arch Pharm (Weinheim). 2020 Sep;353(9):e2000086. (PMID: 32537757); Eur J Pharm Sci. 2012 Dec 18;47(5):834-41. (PMID: 23069618); Bioorg Med Chem. 2021 Feb 15;32:115973. (PMID: 33444846); Bioorg Med Chem. 2014 Feb 1;22(3):1128-38. (PMID: 24411478); Pharmaceuticals (Basel). 2021 Nov 17;14(11):. (PMID: 34832956); Int J Mol Sci. 2018 May 06;19(5):. (PMID: 29734792); Eur J Med Chem. 2013 Nov;69:338-47. (PMID: 24077524); RSC Adv. 2024 Jul 4;14(29):21089-21101. (PMID: 38966815); Eur J Med Chem. 2022 Aug 5;238:114434. (PMID: 35551038); Molecules. 2016 Jul 14;21(7):. (PMID: 27428939); ACS Omega. 2024 Jul 17;9(30):32789-32798. (PMID: 39100360); ACS Omega. 2023 Mar 21;8(13):11806-11812. (PMID: 37033847); J Med Chem. 2015 Apr 23;58(8):3411-31. (PMID: 25654185) |
| Entry Date(s): | Date Created: 20250902 Date Completed: 20250915 Latest Revision: 20250915 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12394826 |
| DOI: | 10.1039/d5ra00534e |
| PMID: | 40895753 |
| Database: | MEDLINE |
Journal Article; Review